Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases

V. Chaudhry; D. R. Cornblath; J. W. Griffin; R. O'Brien; D. B. Drachman

doi:10.1212/WNL.56.1.94

Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases

V. Chaudhry, D. R. Cornblath, J. W. Griffin, R. O'Brien, D. B. Drachman

School of Medicine

Research output: Contribution to journal › Article › peer-review

210 Scopus citations

Abstract

The authors report the use mycophenolate mofetil (MM) in the treatment of neuromuscular diseases. Thirty-eight patients (32 with MG, three with inflammatory myopathy, and three with chronic acquired demyelinating neuropathy) were treated with MM for an average duration of 12 months. All patients tolerated MM without major side effects. Twenty-four patients improved either in their functional status or in their ability to reduce corticosteroid dose. Mean time to improvement was 5 months.

Original language	English (US)
Pages (from-to)	94-96
Number of pages	3
Journal	Neurology
Volume	56
Issue number	1
DOIs	https://doi.org/10.1212/WNL.56.1.94
State	Published - Jan 9 2001

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/WNL.56.1.94

Cite this

@article{86dbdfcf227645c99e267df40636d77b,

title = "Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases",

abstract = "The authors report the use mycophenolate mofetil (MM) in the treatment of neuromuscular diseases. Thirty-eight patients (32 with MG, three with inflammatory myopathy, and three with chronic acquired demyelinating neuropathy) were treated with MM for an average duration of 12 months. All patients tolerated MM without major side effects. Twenty-four patients improved either in their functional status or in their ability to reduce corticosteroid dose. Mean time to improvement was 5 months.",

author = "V. Chaudhry and Cornblath, {D. R.} and Griffin, {J. W.} and R. O'Brien and Drachman, {D. B.}",

year = "2001",

month = jan,

day = "9",

doi = "10.1212/WNL.56.1.94",

language = "English (US)",

volume = "56",

pages = "94--96",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Mycophenolate mofetil

T2 - A safe and promising immunosuppressant in neuromuscular diseases

AU - Chaudhry, V.

AU - Cornblath, D. R.

AU - Griffin, J. W.

AU - O'Brien, R.

AU - Drachman, D. B.

PY - 2001/1/9

Y1 - 2001/1/9

N2 - The authors report the use mycophenolate mofetil (MM) in the treatment of neuromuscular diseases. Thirty-eight patients (32 with MG, three with inflammatory myopathy, and three with chronic acquired demyelinating neuropathy) were treated with MM for an average duration of 12 months. All patients tolerated MM without major side effects. Twenty-four patients improved either in their functional status or in their ability to reduce corticosteroid dose. Mean time to improvement was 5 months.

AB - The authors report the use mycophenolate mofetil (MM) in the treatment of neuromuscular diseases. Thirty-eight patients (32 with MG, three with inflammatory myopathy, and three with chronic acquired demyelinating neuropathy) were treated with MM for an average duration of 12 months. All patients tolerated MM without major side effects. Twenty-four patients improved either in their functional status or in their ability to reduce corticosteroid dose. Mean time to improvement was 5 months.

UR - http://www.scopus.com/inward/record.url?scp=0035830428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035830428&partnerID=8YFLogxK

U2 - 10.1212/WNL.56.1.94

DO - 10.1212/WNL.56.1.94

M3 - Article

C2 - 11148242

AN - SCOPUS:0035830428

SN - 0028-3878

VL - 56

SP - 94

EP - 96

JO - Neurology

JF - Neurology

IS - 1

ER -

Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this